Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Drlica

Showing results (31-40 of 96) with videos related to

Pageof 10
Sort By:
Cell & Bioscience|March 21, 2022
Diabetes as a potential compounding factor in COVID-19-mediated male subfertilityQingkui Jiang, Thomas Linn, Karl Drlica, et al.
Antimicrobial Agents and Chemotherapy|August 29, 2007
Quinolone-mediated bacterial deathKarl Drlica, Muhammad Malik, Robert J Kerns, et al.
Antimicrobial Agents and Chemotherapy|December 27, 2005
Low correlation between MIC and mutant prevention concentrationKarl Drlica, Xilin Zhao, Joseph M Blondeau, et al.
Nature Microbiology|October 4, 2017
Contribution of reactive oxygen species to thymineless death in Escherichia coliYuzhi Hong, Liping Li, Gan Luan, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 6, 2019
Post-stress bacterial cell death mediated by reactive oxygen speciesYuzhi Hong, Jie Zeng, Xiuhong Wang, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2002
Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniaeGlen T Hansen, Kelli Metzler, Karl Drlica, et al.
The Journal of Antimicrobial Chemotherapy|October 2, 2007
Daptomycin inoculum effects and mutant prevention concentration with Staphylococcus aureusBrian Quinn, Syed Hussain, Muhammad Malik, et al.
International Journal of Antimicrobial Agents|January 24, 2006
Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosaGlen T Hansen, Xilin Zhao, Karl Drlica, et al.
Antimicrobial Agents and Chemotherapy|October 29, 2008
In vitro model of mycobacterial growth arrest using nitric oxide with limited airSyed Hussain, Muhammad Malik, Lanbo Shi, et al.
Antimicrobial Agents and Chemotherapy|February 27, 2003
Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureusXilin Zhao, William Eisner, Nathan Perl-Rosenthal, et al.
Pageof 10

Showing results (31-40 of 96) with videos related to

Sort By:
Pageof 10
Cell & Bioscience|March 21, 2022
Diabetes as a potential compounding factor in COVID-19-mediated male subfertilityQingkui Jiang, Thomas Linn, Karl Drlica, et al.
Antimicrobial Agents and Chemotherapy|August 29, 2007
Quinolone-mediated bacterial deathKarl Drlica, Muhammad Malik, Robert J Kerns, et al.
Antimicrobial Agents and Chemotherapy|December 27, 2005
Low correlation between MIC and mutant prevention concentrationKarl Drlica, Xilin Zhao, Joseph M Blondeau, et al.
Nature Microbiology|October 4, 2017
Contribution of reactive oxygen species to thymineless death in Escherichia coliYuzhi Hong, Liping Li, Gan Luan, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 6, 2019
Post-stress bacterial cell death mediated by reactive oxygen speciesYuzhi Hong, Jie Zeng, Xiuhong Wang, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2002
Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniaeGlen T Hansen, Kelli Metzler, Karl Drlica, et al.
The Journal of Antimicrobial Chemotherapy|October 2, 2007
Daptomycin inoculum effects and mutant prevention concentration with Staphylococcus aureusBrian Quinn, Syed Hussain, Muhammad Malik, et al.
International Journal of Antimicrobial Agents|January 24, 2006
Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosaGlen T Hansen, Xilin Zhao, Karl Drlica, et al.
Antimicrobial Agents and Chemotherapy|October 29, 2008
In vitro model of mycobacterial growth arrest using nitric oxide with limited airSyed Hussain, Muhammad Malik, Lanbo Shi, et al.
Antimicrobial Agents and Chemotherapy|February 27, 2003
Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureusXilin Zhao, William Eisner, Nathan Perl-Rosenthal, et al.
Pageof 10